Hologic Opens State-Of-The-Art Learning and Experience Centre In Zaventem, Belgium
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company focused on improving women’s health and well-being through early detection and treatment, today opened its first Learning and Experience Centre in Zaventem, Belgium (a municipality neighboring Brussels). The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) region, centralizing the education experience for Hologic’s technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005071/en/
Hologic Learning & Experience Centre in Zaventem, Belgium. (Photo: Business Wire)
Groundbreaking technologies to minimize doubt and maximize confidence among healthcare professionals
Radiologists, lab technicians, obstetrician-gynecologists and many other healthcare professionals count on Hologic solutions to perform when lives are at stake. The 1,500m2 Learning and Experience Centre contains fully equipped training labs with demonstration capabilities for technologies from all four of Hologic’s divisions (Breast & Skeletal Health, Diagnostic, Gynecological Surgical and Medical Aesthetics) to ensure the highest level of understanding and provide hands-on experience.
“The opening of our new Hologic Learning and Experience Centre in Brussels is a significant milestone in our company’s history and reflects our deep commitment to providing unparalleled training and support to our customers,” said Jan Verstreken, Regional President EMEA and Canada at Hologic. “Hologic is a global champion for women’s health and brings leading-edge technology to healthcare systems around the world. The patient is our greatest priority and when their health is in question, nothing is more important to us than providing the most accurate, effective, and timely diagnosis or treatment. As Hologic continues to gain recognition as a leader in women's health, we commit to supporting the healthcare systems and their patients by ensuring the absolute best use of our truly unique technologies, for the direct benefit of millions of patients in the region.”
A hub for Hologic’s expertise in Brussels, the heart of Europe
For the first time, Hologic will bring training and education for all its products under one roof – located at the heart of Europe – to offer the most cohesive, convenient and interconnected experience. Products featured at the Hologic Learning and Experience Centre include:
- 3Dimensions™ – a mammography system that delivers the fastest, highest resolution 3D™ images and is clinically proven to be more comfortable and enhance workflow.
- Panther Fusion® – a fully automated, integrated molecular testing platform with true sample-to-result automation, adaptable workflow options, and a consolidated testing menu.
- NovaSure® – a minimally invasive, one-time, five-minute endometrial ablation procedure to reduce or stop abnormal uterine bleeding.
- PicoSure® – a laser workstation to remove tattoos and revitalize skin by reducing the appearance of wrinkles, acne scars and pigment-like freckles, sunspots and discoloration.
The creation of Hologic’s European hub and the consolidation of key European functions, including customer service, will create up to 60 new jobs in Belgium over the next 12 months. Each year, the new Learning and Experience Centre is expected to welcome several thousand visitors including healthcare professionals, key opinion leaders, current and prospective customers, distributor partners, and employees.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.
Hologic currently has more than 6.300 employees serving clients in more than 21 countries. Hologic has operated in Belgium since 1992 and currently employs 100 people at its Zaventem facility. For more information, visit www.hologic.com.
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products and future hiring and expansion plans. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Finally, there can be no assurance that Hologic will meet its growth, hiring or expansion goals. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to firstname.lastname@example.org.
SOURCE: Hologic, Inc.
+1 585 355 5978
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation18.4.2019 10:00:00 CEST | Pressemelding
Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005161/en/ Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to pro
Racketeering Lawsuit Filed by Boies Schiller Flexner LLP Alleges Czech Oligarch Defrauds US Hedge Fund and Former Partner Out of Over $1 Billion18.4.2019 07:41:00 CEST | Pressemelding
New York hedge fund, Kingstown Capital Management L.P, and other plaintiffs filed a lawsuit on 10 April 2019 in the Southern District of New York against Radovan Vitek, a Czech real estate mogul with business interests throughout Europe, whose fortune Forbes magazine estimates at $3.5 billion. Represented by litigation powerhouse Boies Schiller Flexner LLP, the hedge fund Kingstown Capital Management L.P and Czech investment firm Investhold Ltd allege that Vitek ran an elaborate criminal enterprise that defrauded the plaintiffs out of more than US $1 billion. According to the complaint, Berlin’s largest commercial real estate landlord, Vitek engaged in racketeering activity including wire fraud, mail fraud, money laundering, and other crimes and amassed his wealth at the expense of the plaintiffs, according to the complaint. His commercial interests span multiple jurisdictions including the Czech Republic, Switzerland, Luxembourg, Germany, Croatia and UK. The complaint alleges that Vit
MHI Thermal Systems Develops Demonstration Unit of the World’s First Small-Capacity Residential Air-Conditioner Adopting the Low-GWP R454C Refrigerant18.4.2019 07:21:00 CEST | Pressemelding
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/ Residential type
Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System18.4.2019 07:00:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005130/en/ ThinPrep Genesis processor (Photo: Business Wire) The Genesis processor is the latest extension of the ThinPrep portfolio, which revolutionized and increased the accuracy of cervical cancer screening with the first liquid-based Pap test in 1996. Hologic launched an updated ThinPrep® 2000 processor in 2017 and received FDA approval in 2018 for the ThinPrep® Integrated Imager, which guides cytotechnologists to ar
Ipsen Completes Acquisition of Clementia Pharmaceuticals18.4.2019 05:00:00 CEST | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO). Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases. The palovarotene regulatory submission for the prevention of heterotopic ossification (HO) in patients with FOP in the U.S.
Sartorius Starts off Fiscal 2019 with a Strong First Quarter18.4.2019 05:00:00 CEST | Pressemelding
Sartorius, a leading international partner of biopharmaceutical research and the industry, started off fiscal 2019 with substantial double-digit growth in order intake, sales revenue and earnings. Consolidated first-quarter sales revenue rose in constant currencies by 16.8% to 435.7 million (reported: +19.4%); order intake increased 16.6% to 482.8 million euros (reported: +19.3%). Sartorius’ underlying EBITDA1) surged 28.7% to 114.0 million euros. Its respective underlying EBITDA margin for the first three months of 2019 was 26.2% (Q1 2018: 24.3%), with a good half a percentage point of this increase resulting from the change in accounting rules2), as expected. Relevant net profit3) for the Group climbed 30.8% to 48.6 million euros. Earnings per ordinary share were 0.71 euros (Q1 2018: 0.54 euros); earnings per preference share, 0.72 euros (Q1 2018: 0.55 euros). “We are very pleased with our first-quarter results,” said Dr. Joachim Kreuzburg, CEO and Executive Board Chairman. “In Biopr